A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group And An Open-Label Single-Blind Cohort Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administrered for 12 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatits

Trial Profile

A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group And An Open-Label Single-Blind Cohort Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administrered for 12 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatits

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs NGM 282 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Sponsors NGM Biopharmaceuticals
  • Most Recent Events

    • 12 Mar 2020 According to a NGM Biopharmaceuticals media release, results demonstrating histological measures of disease were accepted for oral presentation at the International Liver Congress™ 2018, the 53rd annual meeting of the European Association for the Study of the Liver (EASL) 2018.
    • 14 Apr 2018 Results presented in a NGM Biopharmaceuticals media release.
    • 13 Apr 2018 According to a NGM Biopharmaceuticals media release, detailed data ill be highlighted in a late-breaking plenary presentation at The International Liver Congress (ILC) 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top